Search
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[A33105] Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsEfalizumab
go.drugbank.com/drugs/DB00095ApprovedWithdrawnThe FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a.
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … [L32368] Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have
Categories: Adrenergic alpha-1 Receptor AntagonistsBelinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIntravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. … The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, 2-PROPENAMIDE, N-HYDROXY-3-(3-((PHENYLAMINO)SULFONYL)PHENYL)-, (2E)-Cefotaxime
go.drugbank.com/drugs/DB00493ApprovedInvestigationalIn most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Products: CLAFORAN 0.5 G IM/IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, CLAFORAN 2G/40 ML IM/IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.
Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigationalrelief was observed to be 8 hours compared to 36 hours for the placebo treatment. … [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.
Categories: Bradykinin Receptor Antagonists, Bradykinin B2 Receptor AntagonistsRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalOn November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … It was originally approved by the U.S.
Products: MABTHERA ® CONCENTRADO DE SOLUCIÓN PARA INFUSIÓN 500 MG / 50 MLChloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approvedChloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. … [A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.